Daiichi sends Japanese execs to new Ranbaxy plant in India

If it's not an example of closing the barn door after the horse has run away, then it's 20/20 hindsight. Either way, Daiichi Sankyo has dispatched two execs from Japan--a GM and a director--to keep watch at the new Mohali, Punjab, plant of Indian unit Ranbaxy Labs. The plant is expected to be the main source of Ranbaxy drugs bound for the U.S., and it recently earned an OK from the FDA. Daiichi most likely wants it stay that way: The Japanese drug giant is still smarting from lowering profit projections and cutting exec pay to fund anticipated Ranbaxy fines for allegedly falsifying manufacturing records. Daiichi says the move doesn't indicate a lack of confidence in Ranbaxy's current team. Story

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.